Compare Novo Nordisk A/S (NVO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs New York Times Co — how do they compare? Novo Nordisk A/S trades at $46.05 (market cap $207.85B), while New York Times Co trades at $64.32 (market cap $10.28B). The key difference: Novo Nordisk A/S is far larger — about 20.2× New York Times Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | NYT | |
|---|---|---|
Market Cap | $207.85B | $10.28B |
Sector | Health | Media |
52-Week High | $63.98 | $85.86 |
52-Week Low | $35.29 | $54.66 |
Enterprise Value | $222.55B | $9.67B |
Dividend Yield | 3.81% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
The New York Times Company (NYT) trades at $64.80, up 1.98% today, with a bearish technical signal despite recent earnings beats. Fundamentals show strong revenue growth to $2.82 billion in 2025 and a net income margin of 13.19%, though digital subscriber growth concerns have pressured the stock. The current P/E ratio is 26.55, above industry averages, reflecting its premium valuation.
The outlook is mixed; solid profitability and a consensus price target of $77.50 suggest upside, but slowing subscriber additions and high valuation pose risks. Investor sentiment is cautious due to recent price weakness, with analysts predominantly holding a 'Hold' rating, indicating a wait-and-see approach for near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
